Insider Trading June 4, 2026 06:07 PM

Zoom CEO Eric Yuan Executes $2.64 Million Share Sales Under Pre-Arranged Trading Plan

Insider activity coincides with analyst upgrades and the launch of ZoomMate, as the company navigates valuation metrics and competitive positioning.

By Leila Farooq ZM

Eric S. Yuan, Chief Executive Officer of Zoom Communications, Inc. (NASDAQ:ZM), executed a series of transactions involving the conversion and subsequent sale of Class A common stock, totaling approximately $2.64 million. These transactions occurred on June 2 and June 3, 2026, and were facilitated through a Rule 10b5-1 trading plan adopted by Mr. Yuan on June 20, 2025. The sales were conducted at weighted average prices ranging from $105.68 to $113.40 per share. This insider activity unfolds against a backdrop of strong stock performance, with Zoom shares gaining over 30% in the past year and trading at a price-to-earnings ratio of 15.6. Concurrently, the company has introduced ZoomMate, an AI assistant priced at $20 per user monthly, and received multiple analyst price target increases following its first-quarter fiscal 2027 results.

Zoom CEO Eric Yuan Executes $2.64 Million Share Sales Under Pre-Arranged Trading Plan
ZM

Key Points

  • CEO Eric Yuan executed $2.64 million in sales of Class A shares through a Rule 10b5-1 plan on June 2 and 3, 2026, following conversions from Class B shares.
  • Zoom’s stock has gained over 30% in the past year, trading at a P/E of 15.6, with analysts citing undervaluation and strong gross margins of 78%.
  • The company launched ZoomMate, an AI assistant priced at $20 per user monthly, and received multiple analyst price target increases following Q1 fiscal 2027 results.

Eric S. Yuan, the Chief Executive Officer of Zoom Communications, Inc. (NASDAQ:ZM), has completed a series of stock transactions involving the conversion and sale of Class A common shares, resulting in proceeds of approximately $2.64 million. The transactions were executed on June 2 and June 3, 2026, under the parameters of a Rule 10b5-1 trading plan that Mr. Yuan established on June 20, 2025. This structured approach to selling ensures compliance with securities regulations while allowing for predetermined execution of insider transactions.

On June 2, 2026, Mr. Yuan first acquired 12,100 shares of Class A common stock by converting an equivalent number of Class B common stock shares. Immediately following this conversion, he disposed of the entire 12,100 Class A share position. The sales were executed at weighted average prices ranging from $109.06 to $113.40 per share. The following day, June 3, 2026, a parallel transaction occurred where Mr. Yuan again acquired 12,100 shares of Class A common stock through the conversion of Class B shares, which he subsequently sold at weighted average prices between $105.68 and $110.305 per share.

These insider sales occur as Zoom Communications, Inc. demonstrates significant market momentum. The stock has delivered returns exceeding 30% over the past year and currently trades at a price-to-earnings ratio of 15.6. According to InvestingPro analysis, the equity appears undervalued at current levels, supported by the company maintaining a gross profit margin of 78%. The platform’s Fair Value assessment indicates potential upside, positioning Zoom among stocks identified on the Most Undervalued list.

All Class A and Class B shares involved in these reported transactions are held indirectly by Mr. Yuan through the 2018 Yuan and Zhang Revocable Trust, for which he and his spouse serve as cotrustees. Each share of Class B common stock is convertible into one share of Class A common stock at the option of the reporting person and carries no expiration date. In addition to these holdings, Mr. Yuan holds Restricted Stock Units representing contingent rights to receive 38,282 shares and 30,173 shares of Class A common stock. The larger award is subject to vesting in equal quarterly installments over four years from July 8, 2022, while the smaller award vests in equal quarterly installments over three years from July 11, 2023.

Concurrently with the insider activity, Zoom Video Communications Inc. has launched ZoomMate, an AI assistant priced at $20 per user monthly. This product is designed to enhance workplace conversations and task execution across various business applications. ZoomMate integrates with platforms including Salesforce, Jira, Slack, ServiceNow, Google Workspace, and Microsoft applications, and is currently available to customers in North America.

Following the company’s first-quarter fiscal 2027 results, several analyst firms have adjusted their price targets for Zoom. Benchmark raised its target to $125, highlighting the company’s transition into an AI-enabled enterprise platform. Piper Sandler increased its target to $107, noting modest acceleration in performance and revenue. Cantor Fitzgerald also raised its target to $104, emphasizing the adoption of Zoom’s AI products. Rosenblatt increased its price target to $130, citing the earnings beat and raised guidance, with revenue and free cash flow surpassing expectations.

Risks

  • The reliance on a Rule 10b5-1 plan for insider transactions may invite scrutiny regarding the timing and motivation behind sales, potentially impacting investor sentiment in the technology sector.
  • The integration of new AI products like ZoomMate across diverse platforms such as Salesforce, Jira, and Microsoft introduces competitive risks within the enterprise software market.
  • While analyst targets have been raised, the valuation metrics including a 15.6 P/E ratio suggest that future performance must continue to exceed expectations to justify current market pricing.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026